TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Ciarán P. Kelly(Met Éireann), Mark S. Turner, Michael S. Boyne(Astellas Pharma (United States)), Amy Morris(Astellas Pharma (United States)), Mark Matson, Seppo Meri(University of Helsinki), M. Roy First(Eurofins (France)), Daniel A. Leffler(Beth Israel Deaconess Medical Center), Robert Fogel, Barbara Rizzardi, Adam C. Bledsoe(Mayo Clinic), Michele Gerber, Jocelyn A. Silvester, Adam Elhofy(Astellas Pharma (United States)), Paul K. Haynes, Glennda Smithson(Takeda (United States)), Daniel R. Getts(Northwestern University), Tobias Freitag(Orthopädische Universitätsklinik), Michael Koren(Walter Reed Army Institute of Research), Stephen D. Miller(Northwestern University), Joseph A. Murray(Johns Hopkins University), Joseph R. Podojil(Northwestern University), Tsung‐Teh Wu(Analatom (United States)), Thomas H. Oliphant
Cited by 177
Related Papers
Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs
|The Journal of Immunology|2004|1.2k
Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology
|Gut|2014|1.1k
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls
|Scientific Reports|2016|973
Increased Prevalence and Mortality in Undiagnosed Celiac Disease
|Gastroenterology|2009|769